Immune-Onc Therapeutics develops therapeutic antibodies that target myeloid cell surface proteins to enhance the efficacy of immunotherapy for blood cancers and solid tumors. By modulating or depleting specific myeloid cell subsets, the company aims to improve treatment outcomes for the majority of cancer patients who currently do not respond to existing therapies.
Funding
$138.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Existing cancer immunotherapies, such as T-cell checkpoint inhibitors, are ineffective in a large percentage of patients, particularly those with solid tumors and blood cancers like acute myeloid leukemia (AML). These therapies often fail because they do not adequately address the immunosuppressive effects of myeloid cells within the tumor microenvironment.
Solution
Immune-Onc Therapeutics is developing a pipeline of novel therapeutic antibodies designed to modulate or deplete specific subsets of myeloid cells. By targeting myeloid cell surface proteins, these antibodies aim to reprogram the tumor microenvironment, enhance anti-tumor immunity, and improve treatment outcomes for patients who do not respond to current immunotherapies. The company's approach seeks to unlock the full potential of the immune system to fight cancer by addressing the suppressive roles of myeloid cells in both solid tumors and hematological malignancies.
Target Audience
The primary target audience includes cancer patients with solid tumors and blood cancers who are not responsive to existing immunotherapies, as well as researchers and clinicians in the fields of oncology and immunology.
Features
- Antibodies targeting specific myeloid cell surface proteins to modulate immune responses
- Focus on modulating or depleting myeloid cell subsets involved in disease pathogenesis
- Development of immunomodulatory agents for the treatment of autoimmune diseases and cancers
- Aims to enhance the efficacy of existing immunotherapies